Shire shares have taken a beating this year, but they got a boost Friday from third-quarter earnings results investors viewed favorably.
GSK and Reckitt Benckiser have already declared interest in Pfizer’s consumer health unit. But they likely won’t be alone when bidding kicks off.
GlaxoSmithKline said it's looking hard at Pfizer’s OTC unit—but that was bad news to analysts worried about the fate of the company’s dividend.
Eli Lilly is looking at strategic options for animal health business Elanco that could include an IPO, merger, sale, or to keep the business.
When the year began, the prospect of U.S. tax reform had pharma companies salivating for some M&A action. But so far, that hasn't happened.
Obesity drugmaker Orexigen may be game for a sale. The question is, is anyone game for a buy?
Surprise, surprise: Impax Labs, looking to bulk up amid generics pricing pressure and newly helmed by M&A specialist Paul Bisaro, has struck a deal.
What comes after a successful M&A hunt at Gilead Sciences? A promotion for the executive who sewed up its $11.9 billion deal for Kite Pharma.
Reckitt Benckiser’s feelings about Pfizer’s OTC unit haven’t changed since the company said it’d be keen to buy it. But its resources have.
Shire has hinted that a spinoff of its neuroscience unit may be in the works. But one U.S. hedge fund wants more.